We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+8.34%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.32B
AUM Growth
+$160M
Cap. Flow
+$106M
Cap. Flow %
4.55%
Top 10 Hldgs %
55.17%
Holding
93
New
22
Increased
20
Reduced
17
Closed
23

Top Buys

Rank Stock Value
1
AAL icon
American Airlines Group
AAL
+$18.2M
2
AER icon
AerCap
AER
+$17.8M
3
JMEI
Jumei International Holding Limited American depositary shares, each representing ten Class A ordina
JMEI
+$11.1M
4
HAPN
Happen Inc
HAPN
+$10.3M
5
DAL icon
Delta Air Lines
DAL
+$8.74M

Top Sells

Rank Stock Value
1
GOOG icon
Alphabet (Google) Class C
GOOG
+$48.4M
2
BLUE
bluebird bio
BLUE
+$23.6M
3
MET icon
MetLife
MET
+$21.3M
4
AIG icon
American International
AIG
+$19.2M
5
CFG icon
Citizens Financial Group
CFG
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 34.21%
2 Consumer Discretionary 10.58%
3 Financials 3.02%
4 Industrials 2.27%
5 Communication Services 1.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
51
DELISTED
Ignyta, Inc.
RXDX
$6.79M 0.29%
450,000
+25,000
+6% +$303K
MCRB icon
52
Seres Therapeutics
MCRB
$46.3M
$6.64M 0.29%
+8,003
New +$6.98M
CLDX icon
53
Celldex Therapeutics
CLDX
$2.86B
$6.3M 0.27%
+16,667
New +$6.62M
HOUS
54
DELISTED
Anywhere Real Estate
HOUS
$4.67M 0.2%
100,000
-125,000
-56% -$5.81M
XOMA
55
DELISTED
Xoma
XOMA
$4.66M 0.2%
60,000
– –
LCTX icon
56
Lineage Cell Therapeutics
LCTX
$257M
$4.65M 0.2%
1,588,475
– –
AGEN
57
Agenus
AGEN
$280M
$4.58M 0.2%
27,008
+6,112
+29% +$867K
CLLS
58
Cellectis
CLLS
$287M
$4.51M 0.19%
125,000
+25,000
+25% +$878K
HAPN
59
CALL
Happen Inc
HAPN
$2.13B
$3.69M 0.16%
+50,000
New +$4.47M
JOYY
60
JOYY Inc
JOYY
$3.73B
$3.48M 0.15%
+50,000
New +$3.34M
JD icon
61
JD.com
JD
$43.4B
$3.41M 0.15%
+100,000
New +$3.4M
IRWD icon
62
Ironwood Pharmaceuticals
IRWD
$596M
$2.62M 0.11%
258,954
– –
PARN
63
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$2.48M 0.11%
500,000
– –
LCTX icon
64
CALL
Lineage Cell Therapeutics
LCTX
$257M
$2.18M 0.09%
743,407
+247,802
+50% +$961K
ARRY
65
CALL
DELISTED
Array Biopharma Inc
ARRY
$2.16M 0.09%
+300,000
New +$2.21M
CSLT
66
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$2.04M 0.09%
250,000
– –
CERE
67
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$2M 0.09%
1,024,020
-1
-0% -$2
MRTX
68
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.93M 0.08%
61,276
-188,724
-75% -$5.56M
XOMA
69
CALL
DELISTED
Xoma
XOMA
$1.55M 0.07%
+20,000
New +$1.44M
CLCD
70
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$50K ﹤0.01%
+5,575
New +$47.8K
ADVM
71
DELISTED
Adverum Biotechnologies
ADVM
– –
-10,000
Closed -$4.05M
AIG icon
72
American International
AIG
$42.8B
– –
-350,000
Closed -$19.2M
AMZN icon
73
CALL
Amazon
AMZN
$2.48T
– –
-1,000,000
Closed -$18.6M
APTV icon
74
CALL
Aptiv
APTV
$12.4B
– –
-100,000
Closed -$7.97M
APTV icon
75
Aptiv
APTV
$12.4B
– –
-200,000
Closed -$15.9M
1 2
3
4

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2015 Portfolio in Review

As of Q2 2015, Artal Group held 93 positions worth $2.32B, up 7.4% from $2.16B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Artal Group deployed $106M of net new capital in Q2 2015, opening 22 new positions and adding to 20 existing holdings. Its largest new stake was American Airlines Group: 400,000 shares worth $16M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 33% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was bluebird bio, an estimated $23.6M trimmed.

  • Artal Group's largest Q2 2015 buy was American Airlines Group: 400,000 shares worth $16M.
  • Artal Group added most to Happen Inc in Q2 2015, an estimated $10.3M increase.
  • Artal Group's biggest Q2 2015 reduction was bluebird bio, cutting an estimated $23.6M.
  • Artal Group fully exited Alphabet (Google) Class C in Q2 2015, selling an estimated $48.4M.
  • Artal Group's ten largest holdings make up 55% of its $2.32B portfolio in Q2 2015.
  • Artal Group opened 22 new positions and closed 23 in Q2 2015.
  • Artal Group's portfolio value rose 7.4% quarter-over-quarter to $2.32B.

Based on Artal Group's 13F filing for Q2 2015, filed 13 Aug 2015.